Data presented at ADA showed that basal insulin therapy with Lantus® achieved target glycaemic control in poorly controlled type 2 diabetes
Data presented at ADA showed that basal insulin therapy with Lantus® achieved target glycaemic control in poorly controlled type 2 diabetes Two studies show insulin glargine control of HbA1C in poorly controlled type 2 diabetes patients, with comparable rates of hypoglycemia Paris June 13, 2005: Data presented today at the 65th Session of the American Diabetes Association (ADA), San Diego demonstrated that people with type 2 diabetes achieved significantly better glycaemic control, and also achieve it earlier, when treated with the 24-hour basal insulin analog Lantus® (insulin glargine [